share_log

8-K/A: Current report (Amendment)

8-K/A: Current report (Amendment)

8-K/A:重大事件(修正)
美股SEC公告 ·  08/09 05:05

Moomoo AI 已提取核心訊息

On August 8, 2024, Ginkgo Bioworks Holdings, Inc. reported its financial results for the second quarter ended June 30, 2024. The company announced a decrease in total revenue to $56 million, a 30% drop from the previous year, primarily due to a ramp down in K-12 testing in its Biosecurity segment. The Cell Engineering segment also saw a 20% revenue decline. The loss from operations increased to $(223) million, including stock-based compensation and restructuring costs. Ginkgo began a restructuring plan in May 2024, which included workforce reductions and facility consolidations, aiming to complete most actions in 2025. The estimated cost for the reduction in force is between $18.0 million to $22.0 million, primarily in the Cell Engineering segment. The company reaffirmed its 2024 total revenue outlook of $170-$190 million and is taking measures to reach Adjusted EBITDA breakeven by the end of 2026. Ginkgo's cash and cash equivalents balance stood at $730 million at the end of the second quarter.
On August 8, 2024, Ginkgo Bioworks Holdings, Inc. reported its financial results for the second quarter ended June 30, 2024. The company announced a decrease in total revenue to $56 million, a 30% drop from the previous year, primarily due to a ramp down in K-12 testing in its Biosecurity segment. The Cell Engineering segment also saw a 20% revenue decline. The loss from operations increased to $(223) million, including stock-based compensation and restructuring costs. Ginkgo began a restructuring plan in May 2024, which included workforce reductions and facility consolidations, aiming to complete most actions in 2025. The estimated cost for the reduction in force is between $18.0 million to $22.0 million, primarily in the Cell Engineering segment. The company reaffirmed its 2024 total revenue outlook of $170-$190 million and is taking measures to reach Adjusted EBITDA breakeven by the end of 2026. Ginkgo's cash and cash equivalents balance stood at $730 million at the end of the second quarter.
2024年8月8日,金戈生物科技控股公司公佈了截至2024年6月30日第二季度的財務業績。公司宣佈,由於生物安全領域K-12測試的逐漸減少,總營業收入降至5600萬美元,較上年下降了30%。電芯工程領域的收入也下降了20%。包括股票補償和重組成本在內的營業虧損增加到了2.23億美元。金戈於2024年5月開始了一項重組計劃,其中包括減少員工和設施整合,旨在在2025年完成大多數行動。減員的預計成本在1800萬美元到2200萬美元之間,主要集中在電芯工程領域。公司重申了其2024年的總營業收入預期爲1.7億美元至1.9億美元,並採取措施在2026年底前實現調整後的EBITDA盈虧平衡。截至第二季度末,金戈的現金及現金等價物餘額爲7.3億美元。
2024年8月8日,金戈生物科技控股公司公佈了截至2024年6月30日第二季度的財務業績。公司宣佈,由於生物安全領域K-12測試的逐漸減少,總營業收入降至5600萬美元,較上年下降了30%。電芯工程領域的收入也下降了20%。包括股票補償和重組成本在內的營業虧損增加到了2.23億美元。金戈於2024年5月開始了一項重組計劃,其中包括減少員工和設施整合,旨在在2025年完成大多數行動。減員的預計成本在1800萬美元到2200萬美元之間,主要集中在電芯工程領域。公司重申了其2024年的總營業收入預期爲1.7億美元至1.9億美元,並採取措施在2026年底前實現調整後的EBITDA盈虧平衡。截至第二季度末,金戈的現金及現金等價物餘額爲7.3億美元。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息